You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1545 Results
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Updated
Jul 2024
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Updated
Jul 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Daratumumab in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Transplant Ineligible Multiple Myeloma
New Drug Funding Program
    Daratumumab - In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
ODB Limited Use
    lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or have not experienced progression while on a lenalidomide-based regimen in the treatment or maintenance setting, according to clinical criteria
Sep 2022
Regimen
Regimen
Intent: Palliative
Oct 2017
Regimen
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Jun 2019
Regimen
Regimen
Cancer Type:
Gynecologic, 
Vulva
Intent: Palliative
Jun 2019

Pages